Can clearing old cells boost brain and body in MS? new trial aims to find out
NCT ID NCT07270120
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether a combination of two drugs, dasatinib and quercetin, can safely remove aged, damaged cells that may contribute to inflammation and nerve damage in people with secondary progressive multiple sclerosis (MS). The study enrolls 30 adults aged 50-85 who have not taken MS medications recently and have noticed worsening symptoms. Participants take the drugs every two weeks for three months and are followed for one year to see if their physical and cognitive function improves.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) SECONDARY PROGRESSIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State Martha Morehouse Outpatient Care
Columbus, Ohio, 43210, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could Low-Oxygen breathing supercharge gait therapy for MS?
- New CAR-T therapy targets tough MS cases in early safety trial
- CAR t therapy takes on lupus, MS, and more in first human safety trial
- Could donor cells stop MS progression? early trial launches
- Can a home balance game boost brain and body in MS?
- New MS drug trial uses Super-Powered MRI to see inside the brain